Pharma Foods International Co., Ltd.

TSE:2929 Stock Report

Market Cap: JP¥27.6b

Pharma Foods International Valuation

Is 2929 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2929 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2929 (¥955) is trading below our estimate of fair value (¥2650.16)

Significantly Below Fair Value: 2929 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2929?

Key metric: As 2929 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2929. This is calculated by dividing 2929's market cap by their current earnings.
What is 2929's PE Ratio?
PE Ratio8.4x
EarningsJP¥3.21b
Market CapJP¥27.57b

Price to Earnings Ratio vs Peers

How does 2929's PE Ratio compare to its peers?

The above table shows the PE ratio for 2929 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.8x
177A Kohjin Bio
22.7x25.7%JP¥9.1b
4974 Takara Bio
141.9x25.2%JP¥129.8b
2160 GNI Group
19.4x23.4%JP¥141.9b
4587 PeptiDream
19.3x-9.0%JP¥330.5b
2929 Pharma Foods International
8.4xn/aJP¥27.6b

Price-To-Earnings vs Peers: 2929 is good value based on its Price-To-Earnings Ratio (8.4x) compared to the peer average (50.8x).

Price to Earnings Ratio vs Industry

How does 2929's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
2929 8.4xIndustry Avg. 32.6xNo. of Companies11PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 2929 is good value based on its Price-To-Earnings Ratio (8.4x) compared to the Asian Biotechs industry average (32.6x).

Price to Earnings Ratio vs Fair Ratio

What is 2929's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2929 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2929's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,091.50

7D

-1.8%

1Y

-10.0%

Tsumura

JP¥373.7b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,921.00

7D

-0.7%

1Y

81.2%

ASKA Pharmaceutical HoldingsLtd

JP¥57.8b

Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.

4886

JP¥2,037.00

7D

-4.1%

1Y

14.8%